Mer­ck carves out path in first-line ad­vanced cer­vi­cal can­cer with new FDA win for Keytru­da jug­ger­naut

Mer­ck’s PD-(L)1 block­buster Keytru­da has held a steady march in­to ear­li­er lines of ther­a­py, with cer­vi­cal can­cer next up on its check­list. Af­ter flash­ing win­ning da­ta as part of a chemo com­bo last month, Keytru­da now has the FDA’s green light in first-line pa­tients.

The FDA on Wednes­day ap­proved a com­bi­na­tion of Keytru­da plus chemother­a­py with or with­out be­va­cizum­ab to treat first-line per­sis­tent, re­cur­rent or metasta­t­ic cer­vi­cal can­cer, mak­ing it the first PD-(L)1 check­point in­hibitor ap­proved in that set­ting.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.